In Phase C, contributors will acquire ABBV-744 and oral navitoclax. In Phase D, contributors will obtain ABBV-744 and ruxolitinib. Contributors will acquire treatment until finally disorder progression or maybe the members are not able to tolerate the study drugs. - "Our study exposed the very important position of the KLF16/MYC https://abbv-744-preclinical-stud57801.mdkblog.com/37847975/about-abbv-744-as-a-potential-therapeutic-option-for-aggressive-cancers